Accéder au contenu
Merck

GRHL2 suppression of NT5E/CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment.

iScience (2024-05-06)
Bircan Coban, Zi Wang, Chen-Yi Liao, Klara Beslmüller, Mieke A M Timmermans, John W M Martens, Jasmijn H M Hundscheid, Bram Slutter, Annelien J M Zweemer, Elsa Neubert, Erik H J Danen
RÉSUMÉ

Tumor tissues often contain high extracellular adenosine, promoting an immunosuppressed environment linked to mesenchymal transition and immune evasion. Here, we show that loss of the epithelial transcription factor, GRHL2, triggers NT5E/CD73 ecto-enzyme expression, augmenting the conversion of AMP to adenosine. GRHL2 binds an intronic NT5E sequence and is negatively correlated with NT5E/CD73 in breast cancer cell lines and patients. Remarkably, the increased adenosine levels triggered by GRHL2 depletion in MCF-7 breast cancer cells do not suppress but mildly increase CD8 T cell recruitment, a response mimicked by a stable adenosine analog but prevented by CD73 inhibition. Indeed, NT5E expression shows a positive rather than negative association with CD8 T cell infiltration in breast cancer patients. These findings reveal a GRHL2-regulated immune modulation mechanism in breast cancers and show that extracellular adenosine, besides its established role as a suppressor of T cell-mediated cytotoxicity, is associated with enhanced T cell recruitment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-GRHL2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-GRHL2 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL3760, purified immunoglobulin, buffered aqueous glycerol solution